A 40-year-old black male was evaluated at UAB Eye Care for decreasing vision secondary to multiple sclerosis (MS).
During the American Academy of Optometry's Academy 2014, presenters shared how optometrists can help halt the diabetes epidemic and combat associated ocular complications.
During the American Academy of Optometry's Academy 2014, experts elucidated with promising directions for retinal and other posterior eye problems.
For any treatment to be successful, early detection is key. For that reason, genetic testing may play a role in determining the frequency of follow-up in patients who are determined to have high-risk alleles.
The U.S. Food and Drug Administration approved VisionCare Ophthalmic Technologies’ implantable miniature telescope for use in patients living with bilateral end-stage age-related macular degeneration (AMD) who are age 65 or older.
Heidelberg Engineering GmbH recently launched two new products, OCT2, the next generation OCT module for Spectralis diagnostic imaging, and the Heyex picture archiving and communication system (PACS).
Genetic testing in AMD is a relatively new focus for optometrists and an important one to ensure that we are getting a complete view of our patients’ risk for developing advanced AMD. Although we are making some progress, we still have work to do to gain a better understanding of how to incorporate its use into clinical practice.
The U.S. Food and Drug Administration (FDA) recently approved Eylea (afilbercept, Regeneron) for all forms of macular edema after retinal vein occlusion, including branch retinal vein occlusion.
Ohr Pharmaceutical recently announced details of the planned Phase III registration trials for squalamine eye drops (OHR-102) in the treatment of wet age-related macular degeneration (AMD), which are being designed based on guidance provided by the U.S. Food and Drug Administration (FDA) at a recent "end of Phase II" meeting.
When the retina in my left eye detached in early October 2013, I was on a tour bus, somewhere between Canter’s Deli and Griffith Observatory, in Los Angeles. There was a series of flashes, like warning flares, and then a black tide, an oil slick of a blind spot that started down and to the left and crept toward the center of my vision, arcs of lightning heralding its advance. I knew what was happening, but I didn’t want to believe it.